Dry powder inhaler and system for drug delivery
View Patent ↗A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
1. A dry powder medicament cartridge for an inhaler, comprising:
an enclosure configured to hold a medicament;
at least one inlet port to allow flow into the enclosure, and
at least one dispensing port to allow flow out of the enclosure;
wherein the at least one inlet port is configured to direct at least a portion of the flow entering the at least one inlet port at and across the at least one dispensing port within the enclosure in response to a pressure differential, wherein the inlet port is in close proximity to the at least one dispensing port along a horizontal axis and a vertical axis.
2. The dry powder medicament cartridge of claim 1 , wherein the medicament comprises an active ingredient.
3. The dry powder medicament cartridge of claim 2 , wherein the active ingredient is a hormone, an anticoagulant, an immunomodulating agent, a vaccine, a cytotoxic agent, an antibiotic, a vasoactive agent, a neuroactive agent, an anaesthetic, sedative, a steroid, a decongestant, an antiviral, an antisense, an antigen, or an antibody.
4. The dry powder medicament cartridge of claim 2 , wherein the active ingredient is insulin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, follicle stimulating hormone, vasoactive intestinal peptide, parathyroid hormone, parathyroid hormone related protein, glucagon-like peptide-1, exendin, oxyntomodulin, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase, inositol-requiring kinase 1, PC-DAC-modified derivative, or O-glycosylated forms of PC-DAC, parathyroid hormone 1-34, argatroban, or a combination thereof.
5. The dry powder medicament cartridge of claim 4 , wherein the active ingredient is insulin.
6. The dry powder medicament cartridge of claim 4 , wherein the active ingredient is oxyntomodulin.
7. The dry powder medicament cartridge of claim 4 , wherein the active ingredient is glucagon-like peptide-1.
8. The dry powder medicament cartridge of claim 1 , wherein the medicament comprises a diketopiperazine.
9. The dry powder medicament cartridge of claim 8 , wherein the diketopiperazine is
10. The dry powder medicament cartridge of claim 1 , wherein the cartridge comprises one or more colors or markings to identify the medicament.
11. A dry powder medicament cartridge for an inhaler, comprising: an enclosure configured to hold a medicament having one or more exit ports configured to have a smallest dimension less than 3 mm to exclude release of larger powder aggregates and wherein at least one inlet port and the one or more exit ports are in close proximity along a horizontal axis and a vertical axis.
12. The dry powder medicament cartridge of claim 11 , wherein the medicament comprises an active ingredient.
13. The dry powder medicament cartridge of claim 12 , wherein the active ingredient is hormone, an anticoagulant, an immunomodulating agent, a vaccine, a cytotoxic agent, an antibiotic, a vasoactive agent, a neuroactive agent, an anaesthetic, sedative, a steroid, a decongestant, an antiviral, an antisense, an antigen, or an antibody.
14. The dry powder medicament cartridge of claim 12 , wherein the active ingredient is insulin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, follicle stimulating hormone, vasoactive intestinal peptide, parathyroid hormone, parathyroid hormone related protein, glucagon-like peptide-1, exendin, oxyntomodulin, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase, inositol-requiring kinase 1, PC-DAC-modified derivative, or O-glycosylated forms of PC-DAC, parathyroid hormone 1-34, argatroban, or a combination thereof.
15. The dry powder medicament cartridge of claim 14 , wherein the active ingredient is insulin.
16. The dry powder medicament cartridge of claim 14 , wherein the active ingredient is oxyntomodulin.
17. The dry powder medicament cartridge of claim 14 , wherein the active ingredient is glucagon-like peptide-1.
18. The dry powder medicament cartridge of claim 11 , wherein the medicament comprises a diketopiperazine.
19. The dry powder medicament cartridge of claim 18 , wherein the diketopiperazine is
20. The dry powder medicament cartridge of claim 11 , wherein the cartridge comprises one or more colors or markings to identify the medicament.